Drug Trial Radar · NCT02446990
Effects of Ivabradine in Patients With Stable Coronary Artery Disease Without Clinical Heart Failure
Last checked: Nov 19, 2026Latest source record: Jul 26, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
19,102
Actual
Start
Sep 2009
Primary completion
Jan 2014
Study completion Jan 2014
Sponsor
- Lead sponsor
- Institut de Recherches Internationales ServierAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 18, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the effect of ivabradine on cardiovascular events in patients with coronary artery disease.
Conditions
- Coronary Artery Disease
Interventions
IvabradineDrug
5 mg, 7.5 mg or 10 mg tablets to be taken orally twice daily, at 12-hours intervals, in the morning and in the evening during meals up to 48 months.
PlaceboDrug
Matching placebo tablets to be taken orally twice daily, at 12-hours intervals, in the morning and in the evening during meals up to 48 months.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary Composite EndpointTime frame: The events are expressed as the time to occurrence of the first event, defined as the duration between the date of randomisation and the date of first occurrence of event, assessed up to 48 months.
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
Azienda Ospedaliera Universitaria di Ferrara
Ferrara, Italy
Royal Brompton Hospital
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.